Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

(2010) D.L. Richardson et al.   GYNECOLOGIC ONCOLOGY

Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer

(2010) Rebecca L Stone et al.   LANCET ONCOLOGY

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma

(2009) P. Bono et al.   ANNALS OF ONCOLOGY

Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

(2008) Robert Morris et al.   GYNECOLOGIC ONCOLOGY

Weekly topotecan for recurrent platinum resistant ovarian cancer

(2007) Fadi Abushahin et al.   GYNECOLOGIC ONCOLOGY

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY